We collect data from the public registry at ClinicalTrials.gov, which is managed by the US National Library of Medicine. We plan on adding more sources in the future, e.g. the UK Clinical Trials Gateway (UKCTG). We use AI algorithms to transform free-text data into a computer-friendly representation that can be used for matching patients and trials.

TrialJectory compares your medical information to the enrollment criteria of available trials; we recommend the trials that match the profile you’ve provided. Trials matches are ranked based on their compatibility with your personal medical history.
We issue a medically-relevant questionnaire to patients seeking treatment. You can choose to skip any question we ask, but the more information you provide the more thorough our matching process will be. We rank trials for which you have provided all relevant information first.
Interventional trials are ranked above observational trials, and trials without placebos above trials that may administer placebos.
Trials located closer to your home are ranked above trials far away from where you live.

Once you click the “Apply” button, the TrialJectory medical team will view your profile and make sure we have all the required information. We will then approach the trial coordinator or primary investigator on your behalf. You, and your oncologist, will also be able to contact the investigator directly to learn more about the purpose of the trial, its benefits, the drugs and/or procedures that are part of the trial, side effects, etc. Once you decide to apply to a trial, you will have to sign a consent form. Additional tests (such as blood test, CT/MRI etc.) may be required by the trial recruiting team. Only after the clinical trial team has gathered all the information, will you need to make a final decision whether to enroll. Note that you can withdraw from a trial at any point for whatever reasons, even after the trial has started.

A placebo (often called a sugar pill) is an agent that has no effect on the disease or patient, and is used in some clinical trials as a control to measure the success rate of the new medication.
Rather than administering a non-active placebo, today many studies use the current standard of care as a control. This means that patients will be administered either the conventionally available treatment or the new experimental treatment.

There are a few different structures that a trial can take:
In an “open label” clinical trial both clinicians and patients know which treatment is being administered. In a “double blind” trial neither clinicians nor patients know which treatment is being administered. However, it’s important to note that even in blind trials patients are almost always offered, at minimum, the current standard of care, meaning that you will receive treatment while enrolled in a trial. In trials where this is not the case (i.e., patients are not getting the standard treatment), the trial coordinator/investigator will disclose all necessary information to the participant.

We are a team of researchers, data scientists, oncologists and patients like you, with over 100 years of combined accumulated experience. We decided to use our expertise to give cancer patients streamlined access to the most advanced treatment options and help them get better. We realized that by building a smart machine that introduces patients and their doctors to the right clinical trials we can empower them to make better informed decisions about treatment.
When matching patients with trials, we also help the pharmaceutical industry expedite drug approval and support the entire fight against cancer.

We use clincaltrials.gov. to constantly update our database with new trials and trials that have started recruiting patients.